Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update

Visvanathan, Kala and Fabian, Carol J. and Bantug, Elissa and Brewster, Abenaa M. and Davidson, Nancy E. and DeCensi, Andrea and Floyd, Justin D. and Garber, Judy E. and Hofstatter, Erin W. and Khan, Seema A. and Katapodi, Maria C. and Pruthi, Sandhya and Raab, Rachal and Runowicz, Carolyn D. and Somerfield, Mark R.. (2019) Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of clinical oncology, 37 (33). pp. 3152-3165.

PDF - Published Version

Official URL: https://edoc.unibas.ch/72124/

Downloads: Statistics Overview


To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding to use endocrine therapy for breast cancer risk reduction.; An Expert Panel conducted targeted systematic literature reviews to identify new studies.; A randomized clinical trial that evaluated the use of anastrozole for reduction of estrogen receptor-positive breast cancers in postmenopausal women at increased risk of developing breast cancer provided the predominant basis for the update.; In postmenopausal women at increased risk, the choice of endocrine therapy now includes anastrozole (1 mg/day) in addition to exemestane (25 mg/day), raloxifene (60 mg/day), or tamoxifen (20 mg/day). The decision regarding choice of endocrine therapy should take into consideration age, baseline comorbidities, and adverse effect profiles. Clinicians should not prescribe anastrozole, exemestane, or raloxifene for breast cancer risk reduction to premenopausal women. Tamoxifen 20 mg/day for 5 years is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. Data on low-dose tamoxifen as an alternative to the standard dose for both pre- and postmenopausal women with intraepithelial neoplasia are discussed in the Clinical Considerations section of this article. Additional information is available at www.asco.org/breast-cancer-guidelines.
Faculties and Departments:03 Faculty of Medicine > Departement Public Health > Ehemalige Einheiten Public Health > Pflegewissenschaft (Katapodi)
UniBasel Contributors:Katapodi, Maria C
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:American Society of Clinical Oncology
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
edoc DOI:
Last Modified:21 Jul 2023 09:58
Deposited On:06 Dec 2019 14:51

Repository Staff Only: item control page